权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting androgen receptor signaling in prostate cancer in men with African ancestry

靶向非洲血统男性前列腺癌中的雄激素受体信号传导

基本信息

批准号：
10327764
负责人：
Changmeng Cai
金额：
$ 15.25万
依托单位：
UNIVERSITY OF MASSACHUSETTS BOSTON
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-28 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10327764
关键词：
AR gene Address Affect African African American American Androgen Receptor Androgen Therapy Androgens Apoptotic Basic Science Biological Boston CAG repeat Cancer Center Cancer Etiology Cancer Patient Cells Cessation of life Clinical Combined Modality Therapy Critical Pathways DNA Damage DNA Sequence Rearrangement Dana-Farber Cancer Institute Dependence Development Dose European Genetic Genetic Polymorphism Genetic Transcription Genomics Glutamine Grant High Prevalence KDM1A gene Lead Length Ligands Malignant neoplasm of prostate Massachusetts Modeling Molecular Target Mutation N-terminal Nuclear Outcome Pathway interactions Patients Play Population Proteins Receptor Signaling Research Risk Factors Role Testing Therapeutic Translational Research Universities cancer health disparity cancer initiation men polyglutamine programs prostate cancer cell prostate cancer cell line prostate cancer model racial disparity repaired response targeted agent targeted treatment transcription factor tumor progression

项目摘要

ABSTRACT Prostate cancer (PCa) is the second leading cause of cancer-related death in American men. Although men with European ancestry (EA) still represent the largest population of PCa patients, men with African ancestry (AA) are disproportionately affected by PCa with higher prevalence and worse outcomes. Androgen receptor (AR), a ligand-dependent nuclear transcription factor, plays a pivotal role in PCa development, and there are well- established genetic differences in the AR gene and associated pathways between EA versus AA men. However, it remains unclear how these genetic differences alter AR interaction with associated proteins, and their potential role in PCa development and response to AR targeted therapies. In this study, we hypothesize that differences in AR signaling contribute to the biological differences between PCa in AA versus EA men, and that PCa in AA men may have distinct AR-dependencies and be vulnerable to therapies that combine AR-targeted therapies with other targeted agents. To test these hypotheses, Aim 1 will assess the effect of androgen stimulation on PCa cells from AA versus EA patients, and in isogenic cells reflecting the genetic difference of AR. Aim 2 will identify vulnerabilities generated in response to AR-targeted therapies in AA versus EA PCa models.

摘要前列腺癌（PCa）是美国男性癌症相关死亡的第二大原因。虽然男性与欧洲血统（EA）仍然是PCa患者的最大群体，非洲血统（AA）的男性不成比例地受到PCa的影响，患病率更高，结局更差。雄激素受体（AR），a 配体依赖性核转录因子，在前列腺癌的发展中起着关键作用，建立了EA与AA男性之间AR基因和相关通路的遗传差异。然而，在这方面，目前尚不清楚这些遗传差异如何改变AR与相关蛋白的相互作用，在PCa发展和对AR靶向治疗的反应中的作用。在这项研究中，我们假设，在AR信号转导中，AA与EA男性PCa之间的生物学差异，AA中的PCa 男性可能具有不同的AR依赖性，并且容易受到联合收割机AR靶向治疗的影响与其他目标代理人。为了检验这些假设，目标1将评估雄激素刺激对来自AA与EA患者的PCa细胞，以及反映AR遗传差异的同基因细胞。目标2将识别AA与EA PCa模型中响应AR靶向治疗产生的漏洞。